tarsus-logo-stacked-color-532x626.png
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 17, 2024 08:30 ET | Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...
tarsus-logo-stacked-color-532x626.png
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
September 25, 2024 17:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
August 28, 2024 17:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 08, 2024 16:05 ET | Tarsus Pharmaceuticals, Inc
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an...
tarsus-logo-stacked-color-532x626.png
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 29, 2024 16:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus to Participate in Upcoming Investor Conferences
May 29, 2024 17:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024 17:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024 16:05 ET | Tarsus Pharmaceuticals, Inc
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and...
tarsus-logo-stacked-color-532x626.png
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024 17:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...